<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195779</url>
  </required_header>
  <id_info>
    <org_study_id>114294</org_study_id>
    <secondary_id>2010-020312-12</secondary_id>
    <nct_id>NCT01195779</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children</brief_title>
  <official_title>Observer-blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Adjuvanted Quadrivalent Influenza Candidate Vaccines (GSK2584786A) in Children Aged 6 to 35 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this observer-blind study is to evaluate the safety and immunogenicity of&#xD;
      GlaxoSmithKline Biologicals' influenza vaccine GSK2584786A in healthy children 6 to 35 months&#xD;
      of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.&#xD;
  </why_stopped>
  <start_date type="Actual">September 30, 2010</start_date>
  <completion_date type="Actual">March 22, 2011</completion_date>
  <primary_completion_date type="Actual">March 22, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Haemagglutination-inhibition (HI) Antibody Titers</measure>
    <time_frame>at Day 28/ Day 56</time_frame>
    <description>Titers were planned to be expressed as Geometric Mean Titers (GMTs). Analysis was planned to be done for antibodies against all 4 vaccine strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Neutralizing Antibody Titers</measure>
    <time_frame>at Day 28/ Day 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Number of All-CD4 Cytokine Positive Cells</measure>
    <time_frame>at Day 28/ Day 56</time_frame>
    <description>Geometric mean of the number of CD4 cytokine positive T cells per million T cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Fever of at Least Grade 2 or Higher</measure>
    <time_frame>Within 7 days (Day 0 to 6) follow-up period after any dose of study vaccine</time_frame>
    <description>Grade 2 fever was defined as axillary temperature above 38 degrees Celcius.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum HI Antibody Titers</measure>
    <time_frame>on Days 0, 28/56 and 180</time_frame>
    <description>Titers were planned to be expressed as Geometric Mean Titers (GMTs). Analysis was planned to be done for antibodies against all 4 vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neutralising Antibody Titers</measure>
    <time_frame>on Days 0, 28/56 and 180</time_frame>
    <description>Titers were planned to be expressed as Geometric Mean Titers (GMTs). Analysis was planned to be done for antibodies against all 4 vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms</measure>
    <time_frame>during a 7 day follow-up period (Day 0 to 6) after any vaccination</time_frame>
    <description>Solicited local symptoms included pain, redness and swelling at the injection site. Solicited general symptoms included drowsiness, fever, irritability and loss of appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>within 28 days (Day 0 to Day 27) after any vaccination</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Adverse Events With Medically Attended Visits</measure>
    <time_frame>From Day 0 to 179</time_frame>
    <description>A mediaclly attended visit is defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Potential Immune-mediated Diseases</measure>
    <time_frame>From Day 0 to 179</time_frame>
    <description>Potential Immune-Mediated Diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events</measure>
    <time_frame>From Day 0 to 179</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Influenza</condition>
  <condition>Influenza Vaccines</condition>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation A1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation A1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation A2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation A2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation A3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation A3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation B1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation B1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation B2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation B2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation B3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation B3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2321138A vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 2 doses of Fluarix Vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Bio's influenza vaccine GSK2584786A, different formulations</intervention_name>
    <description>Intramuscular injections</description>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation A1 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation A2 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation A3 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation B1 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation B2 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 1 dose of Formulation B3 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation A1 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation A2 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation A3 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation B1 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation B2 Group</arm_group_label>
    <arm_group_label>GSK2584786A vaccine 2 doses of Formulation B3 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Bio's influenza vaccine GSK2321138A</intervention_name>
    <description>Intramuscular injections</description>
    <arm_group_label>GSK2321138A vaccine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix™</intervention_name>
    <description>Intramuscular injections</description>
    <arm_group_label>Fluarix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects must satisfy ALL the following criteria at study entry:&#xD;
&#xD;
          -  Subjects who the investigator believes that parent(s)/Legally Acceptable&#xD;
             Representative(s) [LAR(s)] can and will comply with the requirements of the protocol&#xD;
&#xD;
          -  Children, male or female between, and including, 6 and 35 months of age at the time of&#xD;
             the first vaccination.&#xD;
&#xD;
          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.&#xD;
&#xD;
          -  Healthy subjects as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
          -  Age appropriate scheduled childhood vaccinations completed to the best of&#xD;
             parent(s)/LAR(s) knowledge.&#xD;
&#xD;
          -  Born after gestation period of 36 to 42 weeks inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The following criteria should be checked at the time of study entry. If ANY exclusion&#xD;
        criterion applies, the subject must not be included in the study:&#xD;
&#xD;
          -  Child in &quot;care&quot;&#xD;
&#xD;
          -  Use of any investigational or non-registered product other than the study vaccine(s)&#xD;
             within 30 days preceding the first dose of study vaccine, or planned use during the&#xD;
             study period.&#xD;
&#xD;
          -  Prior receipt of any influenza vaccination or planned administration during the study&#xD;
             period.&#xD;
&#xD;
          -  Planned administration of any vaccine 30 days prior and 30 days after any study&#xD;
             vaccine administration.&#xD;
&#xD;
          -  Chronic administration of immunosuppressants or other immune-modifying drugs within&#xD;
             six months prior to the first vaccine dose.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination.&#xD;
&#xD;
          -  A family history of congenital or hereditary immunodeficiency.&#xD;
&#xD;
          -  A family history of febrile seizures or/and epilepsy&#xD;
&#xD;
          -  Any known or suspected allergy to any constituent of influenza or routine paediatric&#xD;
             vaccines, a history of severe adverse reaction to any previous vaccination; or a&#xD;
             history of anaphylactic-type reaction to any constituent of influenza vaccine.&#xD;
&#xD;
          -  History of any progressive neurological disorders or seizures.&#xD;
&#xD;
          -  Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal&#xD;
             functional abnormality, as determined by medical history or physical examination.&#xD;
&#xD;
          -  Acute disease and/or fever at the time of enrolment:&#xD;
&#xD;
          -  - Fever is defined as temperature ≥ 37.5°C on oral, axillary or tympanic setting, or&#xD;
             ≥38.0°C on rectal setting.&#xD;
&#xD;
          -  Subjects with a minor illness without fever might be enrolled at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the 3 month&#xD;
             preceding the first dose of study vaccine or planned administration during the study&#xD;
             period.&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, render the subject unfit for&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <results_first_submitted>March 22, 2012</results_first_submitted>
  <results_first_submitted_qc>March 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 24, 2012</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunogenicity</keyword>
  <keyword>safety</keyword>
  <keyword>Influenza</keyword>
  <keyword>children</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Since this study was prematurely terminated (not because of safety issues or lack of immunogenicity but for logistic reasons) only 4 of 1120 planned subjects were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
        </group>
        <group group_id="P2">
          <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
        </group>
        <group group_id="P3">
          <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
        </group>
        <group group_id="P4">
          <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
        </group>
        <group group_id="P5">
          <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
        </group>
        <group group_id="P6">
          <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
        </group>
        <group group_id="P7">
          <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
        </group>
        <group group_id="P8">
          <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
        </group>
        <group group_id="P9">
          <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
        </group>
        <group group_id="P10">
          <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
        </group>
        <group group_id="P11">
          <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
        </group>
        <group group_id="P12">
          <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
        </group>
        <group group_id="P13">
          <title>GSK2321138A Vaccine Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
        </group>
        <group group_id="P14">
          <title>Fluarix Group</title>
          <description>Subjects received 2 doses of Fluarix Vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
        </group>
        <group group_id="B2">
          <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
        </group>
        <group group_id="B3">
          <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
        </group>
        <group group_id="B4">
          <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
        </group>
        <group group_id="B5">
          <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
        </group>
        <group group_id="B6">
          <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
        </group>
        <group group_id="B7">
          <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
        </group>
        <group group_id="B8">
          <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
        </group>
        <group group_id="B9">
          <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
        </group>
        <group group_id="B10">
          <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
        </group>
        <group group_id="B11">
          <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
        </group>
        <group group_id="B12">
          <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
        </group>
        <group group_id="B13">
          <title>GSK2321138A Vaccine Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
        </group>
        <group group_id="B14">
          <title>Fluarix Group</title>
          <description>Subjects received 2 doses of Fluarix Vaccine.</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="1"/>
            <count group_id="B9" value="0"/>
            <count group_id="B10" value="0"/>
            <count group_id="B11" value="0"/>
            <count group_id="B12" value="1"/>
            <count group_id="B13" value="0"/>
            <count group_id="B14" value="1"/>
            <count group_id="B15" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="28" spread="NA">Since only a single subject was enrolled in 4 of the study groups, there was insufficient data to calculate the within-group standard deviation.</measurement>
                    <measurement group_id="B8" value="17" spread="NA">Since only a single subject was enrolled in 4 of the study groups, there was insufficient data to calculate the within-group standard deviation.</measurement>
                    <measurement group_id="B12" value="14" spread="NA">Since only a single subject was enrolled in 4 of the study groups, there was insufficient data to calculate the within-group standard deviation.</measurement>
                    <measurement group_id="B14" value="14" spread="NA">Since only a single subject was enrolled in 4 of the study groups, there was insufficient data to calculate the within-group standard deviation.</measurement>
                    <measurement group_id="B15" value="18.25" spread="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Haemagglutination-inhibition (HI) Antibody Titers</title>
        <description>Titers were planned to be expressed as Geometric Mean Titers (GMTs). Analysis was planned to be done for antibodies against all 4 vaccine strains.</description>
        <time_frame>at Day 28/ Day 56</time_frame>
        <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Haemagglutination-inhibition (HI) Antibody Titers</title>
          <description>Titers were planned to be expressed as Geometric Mean Titers (GMTs). Analysis was planned to be done for antibodies against all 4 vaccine strains.</description>
          <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Neutralizing Antibody Titers</title>
        <time_frame>at Day 28/ Day 56</time_frame>
        <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Neutralizing Antibody Titers</title>
          <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Number of All-CD4 Cytokine Positive Cells</title>
        <description>Geometric mean of the number of CD4 cytokine positive T cells per million T cells.</description>
        <time_frame>at Day 28/ Day 56</time_frame>
        <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Number of All-CD4 Cytokine Positive Cells</title>
          <description>Geometric mean of the number of CD4 cytokine positive T cells per million T cells.</description>
          <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Fever of at Least Grade 2 or Higher</title>
        <description>Grade 2 fever was defined as axillary temperature above 38 degrees Celcius.</description>
        <time_frame>Within 7 days (Day 0 to 6) follow-up period after any dose of study vaccine</time_frame>
        <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Fever of at Least Grade 2 or Higher</title>
          <description>Grade 2 fever was defined as axillary temperature above 38 degrees Celcius.</description>
          <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum HI Antibody Titers</title>
        <description>Titers were planned to be expressed as Geometric Mean Titers (GMTs). Analysis was planned to be done for antibodies against all 4 vaccine strains.</description>
        <time_frame>on Days 0, 28/56 and 180</time_frame>
        <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum HI Antibody Titers</title>
          <description>Titers were planned to be expressed as Geometric Mean Titers (GMTs). Analysis was planned to be done for antibodies against all 4 vaccine strains.</description>
          <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Neutralising Antibody Titers</title>
        <description>Titers were planned to be expressed as Geometric Mean Titers (GMTs). Analysis was planned to be done for antibodies against all 4 vaccine strains.</description>
        <time_frame>on Days 0, 28/56 and 180</time_frame>
        <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Neutralising Antibody Titers</title>
          <description>Titers were planned to be expressed as Geometric Mean Titers (GMTs). Analysis was planned to be done for antibodies against all 4 vaccine strains.</description>
          <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
        <description>Solicited local symptoms included pain, redness and swelling at the injection site. Solicited general symptoms included drowsiness, fever, irritability and loss of appetite.</description>
        <time_frame>during a 7 day follow-up period (Day 0 to 6) after any vaccination</time_frame>
        <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
          <description>Solicited local symptoms included pain, redness and swelling at the injection site. Solicited general symptoms included drowsiness, fever, irritability and loss of appetite.</description>
          <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>within 28 days (Day 0 to Day 27) after any vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="1"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O14" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Adverse Events With Medically Attended Visits</title>
        <description>A mediaclly attended visit is defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason.</description>
        <time_frame>From Day 0 to 179</time_frame>
        <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Adverse Events With Medically Attended Visits</title>
          <description>A mediaclly attended visit is defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason.</description>
          <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Potential Immune-mediated Diseases</title>
        <description>Potential Immune-Mediated Diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.</description>
        <time_frame>From Day 0 to 179</time_frame>
        <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Potential Immune-mediated Diseases</title>
          <description>Potential Immune-Mediated Diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.</description>
          <population>This outcome measure was not assessed for any of the study groups since the study was terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Day 0 to 179</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
          </group>
          <group group_id="O3">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O4">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
          </group>
          <group group_id="O5">
            <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O6">
            <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
          </group>
          <group group_id="O7">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O8">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
          </group>
          <group group_id="O9">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O10">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
          </group>
          <group group_id="O11">
            <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
            <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O12">
            <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
          </group>
          <group group_id="O13">
            <title>GSK2321138A Vaccine Group</title>
            <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
          </group>
          <group group_id="O14">
            <title>Fluarix Group</title>
            <description>Subjects received 2 doses of Fluarix Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="1"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GSK2584786A Vaccine 1 Dose of Formulation A1 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
        </group>
        <group group_id="E2">
          <title>GSK2584786A Vaccine 2 Doses of Formulation A1 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.</description>
        </group>
        <group group_id="E3">
          <title>GSK2584786A Vaccine 1 Dose of Formulation A2 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
        </group>
        <group group_id="E4">
          <title>GSK2584786A Vaccine 2 Doses of Formulation A2 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.</description>
        </group>
        <group group_id="E5">
          <title>GSK2584786A Vaccine 1 Dose of Formulation A3 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
        </group>
        <group group_id="E6">
          <title>GSK2584786A Vaccine 2 Doses of Formulation A3 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.</description>
        </group>
        <group group_id="E7">
          <title>GSK2584786A Vaccine 1 Dose of Formulation B1 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
        </group>
        <group group_id="E8">
          <title>GSK2584786A Vaccine 2 Doses of Formulation B1 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.</description>
        </group>
        <group group_id="E9">
          <title>GSK2584786A Vaccine 1 Dose of Formulation B2 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
        </group>
        <group group_id="E10">
          <title>GSK2584786A Vaccine 2 Doses of Formulation B2 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.</description>
        </group>
        <group group_id="E11">
          <title>GSK2584786A Vaccine 1 Dose of Formulation B3 Group</title>
          <description>Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
        </group>
        <group group_id="E12">
          <title>GSK2584786A Vaccine 2 Doses of Formulation B3 Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.</description>
        </group>
        <group group_id="E13">
          <title>GSK2321138A Vaccine Group</title>
          <description>Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).</description>
        </group>
        <group group_id="E14">
          <title>Fluarix Group</title>
          <description>Subjects received 2 doses of Fluarix Vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

